{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:58:13Z","timestamp":1791914293864,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br Dent J"],"published-print":{"date-parts":[[2024,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pemphigus disease and mucous membrane pemphigoid are autoimmune blistering diseases (AIBDs) which may involve both oral and extra-oral tissues. The Bristol Joint Oral Medicine and Dermatology Combined Clinic was set up in 2014, with the primary aim of improving the standard of care for patients with AIBDs. This interdisciplinary approach aimed to address the medical management challenges due to the multisite nature of these AIBDs.<\/jats:p>\n                  <jats:p>We present a narrative report of the clinical work undertaken within this clinic, focused on the management of this patient cohort within a five-year span (2017-2022). This report outlines the multisite nature of AIBDs and the range of topical and systemic treatments that were employed to achieve adequate disease control and optimise outcomes for patients. We reflect on the experiential benefits of this multidisciplinary clinic extended beyond immediate patient benefits to areas such as specialist training, both from a dermatologist's and oral physician's perspective.<\/jats:p>","DOI":"10.1038\/s41415-024-7074-8","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T19:03:52Z","timestamp":1708628632000},"page":"311-316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The management of pemphigus vulgaris and mucous membrane pemphigoid in a joint oral medicine and dermatology clinic: a five-year narrative review"],"prefix":"10.1038","volume":"236","author":[{"given":"Gemma","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Hathway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Shipley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Staines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"7074_CR4187","doi-asserted-by":"crossref","unstructured":"Lamberts A, Euverman H I, Terra J B, Jonkman M F, Horv\u00e1th B. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases. Front Immunol 2018; 9: 248.","DOI":"10.3389\/fimmu.2018.00248"},{"key":"7074_CR4189","doi-asserted-by":"crossref","unstructured":"Carey B, Setterfield J. Mucous membrane pemphigoid and oral blistering diseases. Clin Exp Dermatol 2019; 44: 732-739.","DOI":"10.1111\/ced.13996"},{"key":"7074_CR4191","doi-asserted-by":"crossref","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332.","DOI":"10.1016\/S0140-6736(12)61140-4"},{"key":"7074_CR4193","doi-asserted-by":"crossref","unstructured":"Chan L S, Ahmed A R, Anhalt G J et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138: 370-379.","DOI":"10.1001\/archderm.138.3.370"},{"key":"7074_CR4196","doi-asserted-by":"crossref","unstructured":"Kasperkiewicz M, Kowalewski C, Jab\u0142o\u0144ska S. Pemphigus herpetiformis: from first description until now. J Am Acad Dermatol 2014; 70: 780-787.","DOI":"10.1016\/j.jaad.2013.11.043"},{"key":"7074_CR4198","doi-asserted-by":"crossref","unstructured":"Buonavoglia A, Leone P, Dammacco R et al. Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy. Autoimmun Rev 2019; 18: 349-358.","DOI":"10.1016\/j.autrev.2019.02.005"},{"key":"7074_CR4200","doi-asserted-by":"crossref","unstructured":"Harman K E, Brown D, Exton L S et al. British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol 2017; 177: 1170-1201.","DOI":"10.1111\/bjd.15930"},{"key":"7074_CR4203","doi-asserted-by":"crossref","unstructured":"Langan S M, Smeeth L, Hubbard R, Fleming K M, Smith C J, West J. Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: 180.","DOI":"10.1136\/bmj.a180"},{"key":"7074_CR4205","doi-asserted-by":"crossref","unstructured":"Rosi-Schumacher M, Baker J, Waris J, Seiffert-Sinha K, Sinha A A. Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid. Front Immunol 2023; 14: 1159351.","DOI":"10.3389\/fimmu.2023.1159351"},{"key":"7074_CR4207","doi-asserted-by":"crossref","unstructured":"Broussard K C, Leung T G, Moradi A, Thorne J E, Fine J-D. Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica. Clin Dermatol 2016; 34: 205-213.","DOI":"10.1016\/j.clindermatol.2015.11.006"},{"key":"7074_CR4209","doi-asserted-by":"crossref","unstructured":"Kasperkiewicz M, Ellebrecht C T, Takahashi H et al. Pemphigus. Nat Rev Dis Primers 2017; 3: 17026.","DOI":"10.1038\/nrdp.2017.26"},{"key":"7074_CR4212","doi-asserted-by":"crossref","unstructured":"Kridin K, Sagi S Z, Bergman R. Mortality and Cause of Death in Patients with Pemphigus. Acta Derm Venereol 2017; 97: 607-611.","DOI":"10.2340\/00015555-2611"},{"key":"7074_CR4214","doi-asserted-by":"crossref","unstructured":"Joly P, Horvath B, Patsatsi A et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol 2020; 34: 1900-1913.","DOI":"10.1111\/jdv.16752"},{"key":"7074_CR4216","doi-asserted-by":"crossref","unstructured":"Groves R W. Pemphigus: a brief review. Clin Med (Lond) 2009; 9: 371-375.","DOI":"10.7861\/clinmedicine.9-4-371"},{"key":"7074_CR4218","doi-asserted-by":"crossref","unstructured":"Ahmed A R, Spigelman Z, Cavacini L A, Posner M R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-1779.","DOI":"10.1056\/NEJMoa062930"},{"key":"7074_CR4220","unstructured":"NHS England. Clinical Commissioning Policy: Rituximab for Immunobullous Disease. 2021. Available at https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2021\/06\/cc-policy-rituximab-for-immonobullous-disease-ocular-v2.pdf (accessed January 2024)."},{"key":"7074_CR4224","doi-asserted-by":"crossref","unstructured":"Zillikens D, Wever S, Roth A, Weidenthaler-Barth B, Hashimoto T, Br\u00f6cker E B. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol 1995; 131: 957-958.","DOI":"10.1001\/archderm.131.8.957"},{"key":"7074_CR4226","doi-asserted-by":"crossref","unstructured":"Bernard P, Vaillant L, Labeille B et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995; 131: 48-52.","DOI":"10.1001\/archderm.131.1.48"},{"key":"7074_CR4228","doi-asserted-by":"crossref","unstructured":"Schmidt E, Rashid H, Marzano A V et al. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II. J Eur Acad Dermatol Venereol 2021; 35: 1926-1948.","DOI":"10.1111\/jdv.17395"},{"key":"7074_CR4230","doi-asserted-by":"crossref","unstructured":"Parker S R, MacKelfresh J. Autoimmune blistering diseases in the elderly. Clin Dermatol 2011; 29: 69-79.","DOI":"10.1016\/j.clindermatol.2010.07.010"},{"key":"7074_CR4234","doi-asserted-by":"crossref","unstructured":"Du G, Patzelt S, van Beek N, Schmidt E. Mucous membrane pemphigoid. Autoimmun Rev 2022; 21: 103036.","DOI":"10.1016\/j.autrev.2022.103036"},{"key":"7074_CR4236","doi-asserted-by":"crossref","unstructured":"Taylor J, McMillan R, Shephard M et al. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 120: 161-171.","DOI":"10.1016\/j.oooo.2015.01.024"},{"key":"7074_CR4238","doi-asserted-by":"crossref","unstructured":"Rashid H, Lamberts A, Borradori L et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I. J Eur Acad Dermatol Venereol 2021; 35: 1750-1764.","DOI":"10.1111\/jdv.17397"},{"key":"7074_CR4240","doi-asserted-by":"crossref","unstructured":"Daniel B S, Murrell D F. Review of autoimmune blistering diseases: the Pemphigoid diseases. J Eur Acad Dermatol Venereol 2019; 33: 1685-1694.","DOI":"10.1111\/jdv.15679"},{"key":"7074_CR4243","doi-asserted-by":"crossref","unstructured":"Finn D J, Graham C, Holt D J, Kelly R, Rajlawat B P, Yesudian P D. Management of mucous membrane pemphigoid in a joint oral medicine-dermatology clinic. Clin Exp Dermatol 2020; 45: 685-690.","DOI":"10.1111\/ced.14188"},{"key":"7074_CR4245","doi-asserted-by":"crossref","unstructured":"Staines K, Hampton P J. Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: a case series. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114: 49-56.","DOI":"10.1016\/j.oooo.2012.01.030"},{"key":"7074_CR4247","unstructured":"NHS England. Dermatology: GIRFT Programme National Specialty Report. 2021. Available at https:\/\/gettingitrightfirsttime.co.uk\/girft-reports\/ (accessed January 2024)."},{"key":"7074_CR4250","doi-asserted-by":"crossref","unstructured":"Theodorakopoulou E, Dalamaga M, Katsimbri P, Boumpas D T, Papadavid E. How does the joint dermatology-rheumatology clinic benefit both patients and dermatologists? Dermatol Ther 2020; 33: 13283.","DOI":"10.1111\/dth.13283"}],"container-title":["British Dental Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41415-024-7074-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41415-024-7074-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41415-024-7074-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T19:06:46Z","timestamp":1708628806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41415-024-7074-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,2,23]]}},"alternative-id":["7074"],"URL":"https:\/\/doi.org\/10.1038\/s41415-024-7074-8","relation":{},"ISSN":["0007-0610","1476-5373"],"issn-type":[{"value":"0007-0610","type":"print"},{"value":"1476-5373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"29 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"Guest Editor, Konrad Staines, was not involved in the peer review process of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"This article is a service evaluation that reviews the work undertaken in a specialist-led combined clinic and was approved by the consultants involved in the care of these patients. It was deemed that formal approval from an ethics committee was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"Data were collected retrospectively and anonymised, therefore consent was not required to participate. All patient details have been modified so that patients cannot be identified. Written consent to publish was obtained for Fig 5.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}}]}}